RxDoctor Payments Data

Melissa Locklear

Family · Rowland, NCNPI 1023355195

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 63 payments — averaging $24.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$381
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$226
  • Indivior Inc.$188
  • AbbVie$174
  • Forte Bio-pharma LLC$127
  • Idorsia Pharmaceuticals US Inc$75
  • plus $353 from 14 others

What the payments were for

  • Food & beverage$1,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$19,441
Medicare patients
29
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$56,686
LinzessLinaclotide49$26,594
SublocadeBuprenorphine12$24,230
CaplytaLumateperone Tosylate12$22,070
RybelsusSemaglutide23$21,812
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl174$16,300
JardianceEmpagliflozin16$9,649
FarxigaDapagliflozin Propanediol14$8,844
EliquisApixaban15$8,719
Breo ElliptaFluticasone/Vilanterol16$6,675
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen238$6,630
Gabapentin292$3,751
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen126$3,146
Albuterol Sulfate HfaAlbuterol Sulfate119$2,228
Pregabalin56$1,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$381$78,49879 claims
AbbVieLinzess$174$26,59449 claims
Indivior Inc.Sublocade$188$24,23012 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$226$22,07012 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$25$16,300174 claims
Boehringer IngelheimJardiance$38$9,64916 claims
AstraZenecaFarxiga$23$8,84414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,522 family providers in North Carolina.

Other family in Rowland

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →